Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Emerging Trends in Artificial Blood


Affiliations
1 Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India
     

   Subscribe/Renew Journal


Blood substitutes are currently undergoing preliminary clinical trials to determine their safety. Two distinctly different classes of oxygen carriers are being developed, each capable of transporting and delivering oxygen to peripheral tissues. The delivery of oxygen by these two methodologies may have both benefits and risks which are unique to its class. Early clinical trials have been promising. However, effective use of these blood substitutes may involve using them in conjunction with other techniques such as normovolemic hemodilution to effectively reduce or eliminate the need for transfusions in certain instances. However, this first generation of clinically safe blood substitutes will not replace allogeneic blood transfusions as a means of treating many types of anemia.

Keywords

Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon-Based Oxygen Carriers (PFBOCs),Blood Substitute, Blood Pharming.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 235

PDF Views: 0




  • Emerging Trends in Artificial Blood

Abstract Views: 235  |  PDF Views: 0

Authors

K. Saranya
Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India
V. Manivasagan
Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India
N. G. Ramesh Babu
Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India
D. Pradeep
Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India
S. Pandidurai
Department of Biotechnology, Adhiyamaan College of Engineering, Hosur, India

Abstract


Blood substitutes are currently undergoing preliminary clinical trials to determine their safety. Two distinctly different classes of oxygen carriers are being developed, each capable of transporting and delivering oxygen to peripheral tissues. The delivery of oxygen by these two methodologies may have both benefits and risks which are unique to its class. Early clinical trials have been promising. However, effective use of these blood substitutes may involve using them in conjunction with other techniques such as normovolemic hemodilution to effectively reduce or eliminate the need for transfusions in certain instances. However, this first generation of clinically safe blood substitutes will not replace allogeneic blood transfusions as a means of treating many types of anemia.

Keywords


Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon-Based Oxygen Carriers (PFBOCs),Blood Substitute, Blood Pharming.